
Global Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2024-2032
Description
Global Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2024-2032
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2024-2032
The global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market size was valued at USD 21.70 billion in 2023. It is expected to grow at a CAGR of 5.40% during the forecast period of 2024-2032, driven by the increasing rates of chronic conditions such as arthritis, chronic back pain, and other inflammatory diseases. The market is experiencing robust growth and is expected to reach USD 34.84 billion by 2032.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Analysis
The global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market is a significant segment of the pharmaceutical industry, renowned for its widespread use in managing pain, inflammation, and fever. NSAIDs inhibit enzymes involved in the inflammation process, offering relief without steroids' adverse effects. This market analysis provides an overview of the drivers, challenges, and future opportunities shaping the landscape of the NSAID market.
Market Drivers
- Prevalence of Chronic Diseases: Increasing rates of chronic conditions such as arthritis, chronic back pain, and other inflammatory diseases drive demand for NSAIDs.
- Aging Population: As the global population ages, the incidence of age-related musculoskeletal conditions like osteoarthritis increases, boosting the demand for effective pain management solutions such as NSAIDs.
- Over-the-Counter Availability: Many NSAIDs are available over the counter, making them easily accessible to consumers for managing pain and mild inflammatory conditions, which supports market growth.
- Advancements in Drug Formulation: There is ongoing development to create NSAIDs with fewer gastrointestinal side effects, enhancing patient compliance and expanding the market.
- Side Effects and Health Risks: NSAIDs are associated with potential side effects, including increased risk of gastrointestinal bleeding, kidney damage, and cardiovascular issues, which can hinder their use, particularly among the elderly.
- Regulatory Scrutiny: Given the risks associated with prolonged NSAID use, these drugs face significant regulatory scrutiny, which can impact market growth. Companies must navigate complex approval processes for new formulations or indications.
- Market Saturation: The NSAIDs market is mature, with numerous established products competing for market share, making it challenging for new entrants to establish a foothold.
- Shift Towards Alternative Therapies: There is a growing consumer preference for natural and alternative treatments for pain and inflammation, such as turmeric, ginger, and omega-3 supplements, which could restrict NSAID sales.
- Targeted Drug Delivery Systems: Developing targeted delivery systems that reduce side effects can provide significant opportunities for growth. These systems would deliver the drug directly to the site of inflammation, minimizing systemic exposure and associated risks.
- Biologics for Inflammation: While biologics are more commonly associated with specific diseases like rheumatoid arthritis, integrating NSAID therapy with biologics for broader anti-inflammatory applications could open new market segments.
- Expansion in Emerging Markets: Increasing healthcare access and rising income levels in emerging markets present significant opportunities for the expansion of the NSAIDs market. These regions have large populations that are beginning to access more comprehensive healthcare services.
- Personalised Pain Management Plans: With advancements in personalized medicine, developing NSAID regimens tailored to individual genetic profiles could enhance efficacy and minimize risks, creating new market niches.
The global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market remains a cornerstone in pain management and anti-inflammatory treatments across various medical fields. As healthcare systems continue to evolve, the demand for NSAIDs is influenced by several emerging trends that cater to both patient needs and industry advancements.
Market Trends
- Development of Safer Formulations: There is a noticeable trend towards the development of NSAIDs with improved safety profiles. Companies are focusing on formulating drugs that offer the therapeutic benefits of traditional NSAIDs but with reduced risks of gastrointestinal and cardiovascular side effects. This includes the incorporation of protective agents and the development of selective COX-2 inhibitors.
- Increased Use of Topical Agents: The market is seeing a rise in the popularity of topical NSAIDs, which are perceived as safer alternatives to their oral counterparts because they are less likely to cause systemic side effects. These formulations are particularly popular among patients who require localized pain relief.
- Integration with Digital Health Tools: There is a growing integration of NSAIDs into treatment plans that are monitored through digital health tools, such as apps that track dosage and patient symptoms. This trend is in line with the broader movement towards personalized medicine and could help improve compliance and outcomes.
- Expanding Indications: Researchers are exploring new therapeutic indications for NSAIDs, extending their use beyond traditional pain and inflammation management. This includes potential roles in cancer prevention and neuroprotective treatments, which could open new avenues for market growth.
- Global Health Initiatives: Efforts to improve access to essential medicines in low- and middle-income countries are driving the adoption of affordable NSAIDs in these regions. These initiatives, often supported by governments and international health organizations, are aimed at addressing the burden of chronic pain and inflammatory diseases on a global scale.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Segmentation
Market Breakup by Disease
- Arthritis
- Migraine
- Ophthalmic Diseases
- Others
Market Breakup by Drugs
- Over-the-Counter Drugs
- Aspirin
- Ibuprofen
- Naproxen
- Naproxen
- Celecoxib
- Others
- Prescription
- Daypro
- Indocin
- Lodine
- Naprosyn
- Relafen
- Vimovo
- Voltaren
Market Breakup by Route of Administration
- Oral
- Parenteral
The parenteral segment, which includes injections and intravenous administrations, is essential for more immediate and targeted effects, particularly in acute care settings or when oral administration is not feasible. This route is especially significant for postoperative pain management or severe inflammatory responses that require rapid relief. While smaller than the oral segment, the parenteral route is expected to grow steadily, driven by its critical role in hospitals and emergency care settings.
Market Breakup by Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Competitive Landscape
The competitive landscape of the NSAIDs market features prominent players like Assertio Holdings, Inc., Bayer AG, Amgen Inc., Lion Corporation, Dr. Reddy’s Laboratories Ltd., Novartis AG, Pfizer Inc., Johnson & Johnson Private Limited, GlaxoSmithKline plc, and Sanofi India. These companies are actively engaged in mergers and acquisitions to expand their market presence and enhance their product portfolios. Significant research initiatives are undertaken to innovate and improve NSAID formulations. Regular product introductions and strategic partnerships are common to stay competitive and meet the growing demand for effective pain management solutions. These activities collectively drive market growth and foster advancements in the NSAIDs sector.
Key Questions Answered in the Report
- What is the current and future performance of the non-steroidal anti-inflammatory drugs market?
- What are the main challenges facing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market?
- What are the key drivers of the non-steroidal anti-inflammatory drugs market?
- What emerging trends are shaping the future of the non-steroidal anti-inflammatory drugs market?
- What factors contribute to the dominance of hospital pharmacies and the growth of online pharmacies?
- What are the key drivers of growth in the global NSAIDs market across different regions?
- Why is the parenteral segment crucial for immediate and targeted effects in acute care settings?
- How does the prevalence of arthritis impact the NSAIDs market in terms of disease segmentation?
- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global non-steroidal anti-inflammatory drugs industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
200 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Overview
- 3.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Historical Value (2017-2023)
- 3.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Landscape*
- 5.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Product Landscape
- 5.2.1 Analysis by Disease Indication
- 5.2.2 Analysis by Route of Administration
- 6 Global Infectious Diseases Epidemiology Snapshot
- 6.1 Global Infectious Disease Incidence Number Overview (2017 – 2032)
- 6.2 Global Infectious Disease Incidence – by Disease (2017 – 2032)
- 6.2.1 Arthritis
- 6.2.2 Migraine
- 6.2.3 Ophthalmic Diseases
- 7 Global Non- Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Dynamics
- 7.1 Market Drivers and Constraints
- 7.2 SWOT Analysis
- 7.2.1 Strengths
- 7.2.2 Weaknesses
- 7.2.3 Opportunities
- 7.2.4 Threats
- 7.3 PESTEL Analysis
- 7.3.1 Political
- 7.3.2 Economic
- 7.3.3 Social
- 7.3.4 Technological
- 7.3.5 Legal
- 7.3.6 Environment
- 7.4 Porter’s Five Forces Model
- 7.4.1 Bargaining Power of Suppliers
- 7.4.2 Bargaining Power of Buyers
- 7.4.3 Threat of New Entrants
- 7.4.4 Threat of Substitutes
- 7.4.5 Degree of Rivalry
- 7.5 Key Demand Indicators
- 7.6 Key Price Indicators
- 7.7 Industry Events, Initiatives, and Trends
- 7.8 Value Chain Analysis
- 8 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Segmentation (2017-2032)
- 8.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
- 8.1.1 Market Overview
- 8.1.2 Arthritis
- 8.1.3 Migraine
- 8.1.4 Ophthalmic Diseases
- 8.1.5 Others
- 8.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
- 8.2.1 Over-the-Counter Drugs
- 8.2.1.1 Aspirin
- 8.2.1.2 Ibuprofen
- 8.2.1.3 Naproxen
- 8.2.1.4 Naproxen
- 8.2.1.5 Celecoxib
- 8.2.1.6 Others
- 8.2.2 Prescription
- 8.2.2.1 Daypro
- 8.2.2.2 Indocin
- 8.2.2.3 Lodine
- 8.2.2.4 Naprosyn
- 8.2.2.5 Relafen
- 8.2.2.6 Vimovo
- 8.2.2.7 Voltaren
- 8.3 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
- 8.3.1 Market Overview
- 8.3.2 Oral
- 8.3.3 Parenteral
- 8.4 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
- 8.4.1 Market Overview
- 8.4.2 Hospital Pharmacy
- 8.4.3 Retail Pharmacy
- 8.4.4 Online Pharmacy
- 8.4.5 Others
- 8.5 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Region
- 8.5.1 Market Overview
- 8.5.2 North America
- 8.5.3 Europe
- 8.5.4 Asia Pacific
- 8.5.5 Latin America
- 8.5.6 Middle East and Africa
- 9 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
- 9.1 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
- 9.1.1 Market Overview
- 9.1.2 Arthritis
- 9.1.3 Migraine
- 9.1.4 Ophthalmic Diseases
- 9.1.5 Others
- 9.2 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
- 9.2.1 Over-the-Counter Drugs
- 9.2.1.1 Aspirin
- 9.2.1.2 Ibuprofen
- 9.2.1.3 Naproxen
- 9.2.1.4 Naproxen
- 9.2.1.5 Celecoxib
- 9.2.1.6 Others
- 9.2.2 Prescription
- 9.2.2.1 Daypro
- 9.2.2.2 Indocin
- 9.2.2.3 Lodine
- 9.2.2.4 Naprosyn
- 9.2.2.5 Relafen
- 9.2.2.6 Vimovo
- 9.2.2.7 Voltaren
- 9.3 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
- 9.3.1 Market Overview
- 9.3.2 Oral
- 9.3.3 Parenteral
- 9.4 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
- 9.4.1 Market Overview
- 9.4.2 Hospital Pharmacy
- 9.4.3 Retail Pharmacy
- 9.4.4 Online Pharmacy
- 9.4.5 Others
- 9.5 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
- 9.5.1 United States of America
- 9.5.2 Canada
- 10 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
- 10.1 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
- 10.1.1 Market Overview
- 10.1.2 Arthritis
- 10.1.3 Migraine
- 10.1.4 Ophthalmic Diseases
- 10.1.5 Others
- 10.2 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
- 10.2.1 Over-the-Counter Drugs
- 10.2.1.1 Aspirin
- 10.2.1.2 Ibuprofen
- 10.2.1.3 Naproxen
- 10.2.1.4 Celecoxib
- 10.2.1.5 Others
- 10.2.2 Prescription
- 10.2.2.1 Daypro
- 10.2.2.2 Indocin
- 10.2.2.3 Lodine
- 10.2.2.4 Naprosyn
- 10.2.2.5 Relafen
- 10.2.2.6 Vimovo
- 10.2.2.7 Voltaren
- 10.3 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
- 10.3.1 Market Overview
- 10.3.2 Oral
- 10.3.3 Parenteral
- 10.4 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
- 10.4.1 Market Overview
- 10.4.2 Hospital Pharmacy
- 10.4.3 Retail Pharmacy
- 10.4.4 Online Pharmacy
- 10.4.5 Others
- 10.5 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
- 10.5.1 United Kingdom
- 10.5.2 Germany
- 10.5.3 France
- 10.5.4 Italy
- 10.5.5 Others
- 11 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
- 11.1 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
- 11.1.1 Market Overview
- 11.1.2 Arthritis
- 11.1.3 Migraine
- 11.1.4 Ophthalmic Diseases
- 11.1.5 Others
- 11.2 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
- 11.2.1 Over-the-Counter Drugs
- 11.2.1.1 Aspirin
- 11.2.1.2 Ibuprofen
- 11.2.1.3 Naproxen
- 11.2.1.4 Naproxen
- 11.2.1.5 Celecoxib
- 11.2.1.6 Others
- 11.2.2 Prescription
- 11.2.2.1 Daypro
- 11.2.2.2 Indocin
- 11.2.2.3 Lodine
- 11.2.2.4 Naprosyn
- 11.2.2.5 Relafen
- 11.2.2.6 Vimovo
- 11.2.2.7 Voltaren
- 11.3 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
- 11.3.1 Market Overview
- 11.3.2 Oral
- 11.3.3 Parenteral
- 11.4 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
- 11.4.1 Market Overview
- 11.4.2 Hospital Pharmacy
- 11.4.3 Retail Pharmacy
- 11.4.4 Online Pharmacy
- 11.4.5 Others
- 11.5 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
- 11.5.1 China
- 11.5.2 Japan
- 11.5.3 India
- 11.5.4 ASEAN
- 11.5.5 Australia
- 11.5.6 Others
- 12 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
- 12.1 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
- 12.1.1 Market Overview
- 12.1.2 Arthritis
- 12.1.3 Migraine
- 12.1.4 Ophthalmic Diseases
- 12.1.5 Others
- 12.2 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
- 12.2.1 Over-the-Counter Drugs
- 12.2.1.1 Aspirin
- 12.2.1.2 Ibuprofen
- 12.2.1.3 Naproxen
- 12.2.1.4 Naproxen
- 12.2.1.5 Celecoxib
- 12.2.1.6 Others
- 12.2.2 Prescription
- 12.2.2.1 Daypro
- 12.2.2.2 Indocin
- 12.2.2.3 Lodine
- 12.2.2.4 Naprosyn
- 12.2.2.5 Relafen
- 12.2.2.6 Vimovo
- 12.2.2.7 Voltaren
- 12.3 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.4 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
- 12.4.1 Market Overview
- 12.4.2 Hospital Pharmacy
- 12.4.3 Retail Pharmacy
- 12.4.4 Online Pharmacy
- 12.4.5 Others
- 12.5 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
- 12.5.1 Brazil
- 12.5.2 Argentina
- 12.5.3 Mexico
- 12.5.4 Others
- 13 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
- 13.1 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
- 13.1.1 Market Overview
- 13.1.2 Arthritis
- 13.1.3 Migraine
- 13.1.4 Ophthalmic Diseases
- 13.1.5 Others
- 13.2 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
- 13.2.1 Over-the-Counter Drugs
- 13.2.1.1 Aspirin
- 13.2.1.2 Ibuprofen
- 13.2.1.3 Naproxen
- 13.2.1.4 Naproxen
- 13.2.1.5 Celecoxib
- 13.2.1.6 Others
- 13.2.2 Prescription
- 13.2.2.1 Daypro
- 13.2.2.2 Indocin
- 13.2.2.3 Lodine
- 13.2.2.4 Naprosyn
- 13.2.2.5 Relafen
- 13.2.2.6 Vimovo
- 13.2.2.7 Voltaren
- 13.3 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Oral
- 13.3.3 Parenteral
- 13.4 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
- 13.4.1 Market Overview
- 13.4.2 Hospital Pharmacy
- 13.4.3 Retail Pharmacy
- 13.4.4 Online Pharmacy
- 13.4.5 Others
- 13.5 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
- 13.5.1 Saudi Arabia
- 13.5.2 United Arab Emirates
- 13.5.3 Nigeria
- 13.5.4 South Africa
- 13.5.5 Others
- 14 Regulatory Framework
- 14.1 Regulatory Overview
- 14.2 US FDA
- 14.3 EU EMA
- 14.4 INDIA CDSCO
- 14.5 JAPAN PMDA
- 14.6 Others
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication Year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Strategic Initiative
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share Analysis, By Region (Top 5 Companies)
- 17.1.1 Market Share Analysis: Global
- 17.1.2 Market Share Analysis: North America
- 17.1.3 Market Share Analysis: Europe
- 17.1.4 Market Share Analysis: Asia-Pacific
- 17.1.5 Market Share Analysis: Others
- 17.2 Assertio Holdings, Inc .
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Bayer AG
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Amgen Inc
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Lion Corporation
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Dr. Reddy’s Laboratories Ltd .
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Novartis AG
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Pfizer Inc .
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Johnson & Johnson Private Limited
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 GlaxoSmithKline plc
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Sanofi India Limited
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 18 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive, moreover we can provide analysis of companies as per custom request.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.